Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1989 Apr;2(Suppl):S134–S138. doi: 10.1128/cmr.2.suppl.s134

Vaccines for prevention of meningococcal disease.

C E Frasch 1
PMCID: PMC358090  PMID: 2497956

Full text

PDF
S134

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  2. Beuvery E. C., Miedema F., van Delft R., Haverkamp J. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect Immun. 1983 Apr;40(1):39–45. doi: 10.1128/iai.40.1.39-45.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beuvery E. C., vd Kaaden A., Kanhai V., Leussink A. B. Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods. Vaccine. 1983 Dec;1(1):31–36. doi: 10.1016/0264-410x(83)90010-5. [DOI] [PubMed] [Google Scholar]
  4. Brodeur B. R., Larose Y., Tsang P., Hamel J., Ashton F., Ryan A. Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. Infect Immun. 1985 Nov;50(2):510–516. doi: 10.1128/iai.50.2.510-516.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Densen P., Weiler J. M., Griffiss J. M., Hoffmann L. G. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med. 1987 Apr 9;316(15):922–926. doi: 10.1056/NEJM198704093161506. [DOI] [PubMed] [Google Scholar]
  6. Eskola J., Peltola H., Takala A. K., Käyhty H., Hakulinen M., Karanko V., Kela E., Rekola P., Rönnberg P. R., Samuelson J. S. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med. 1987 Sep 17;317(12):717–722. doi: 10.1056/NEJM198709173171201. [DOI] [PubMed] [Google Scholar]
  7. Frasch C. E., Zahradnik J. M., Wang L. Y., Mocca L. F., Tsai C. M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis. 1988 Oct;158(4):710–718. doi: 10.1093/infdis/158.4.710. [DOI] [PubMed] [Google Scholar]
  8. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969 Jun 1;129(6):1367–1384. doi: 10.1084/jem.129.6.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gotschlich E. C., Rey M., Triau R., Sparks K. J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest. 1972 Jan;51(1):89–96. doi: 10.1172/JCI106801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Granoff D. M., Munson R. S., Jr Prospects for prevention of Haemophilus influenzae type b disease by immunization. J Infect Dis. 1986 Mar;153(3):448–461. doi: 10.1093/infdis/153.3.448. [DOI] [PubMed] [Google Scholar]
  11. Jennings H. J., Gamian A., Ashton F. E. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J Exp Med. 1987 Apr 1;165(4):1207–1211. doi: 10.1084/jem.165.4.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jennings H. J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol. 1981 Sep;127(3):1011–1018. [PubMed] [Google Scholar]
  13. Jennings H. J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol. 1986 Sep 1;137(5):1708–1713. [PubMed] [Google Scholar]
  14. Käyhty H., Karanko V., Peltola H., Sarna S., Mäkelä P. H. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980 Dec;142(6):861–868. doi: 10.1093/infdis/142.6.861. [DOI] [PubMed] [Google Scholar]
  15. Lepow M. L., Beeler J., Randolph M., Samuelson J. S., Hankins W. A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis. 1986 Dec;154(6):1033–1036. doi: 10.1093/infdis/154.6.1033. [DOI] [PubMed] [Google Scholar]
  16. Mandrell R. E., Zollinger W. D. Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J Immunol Methods. 1984 Feb 24;67(1):1–11. doi: 10.1016/0022-1759(84)90080-2. [DOI] [PubMed] [Google Scholar]
  17. Moreno C., Lifely M. R., Esdaile J. Effect of aluminum ions on chemical and immunological properties of meningococcal group B polysaccharide. Infect Immun. 1985 Sep;49(3):587–592. doi: 10.1128/iai.49.3.587-592.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Moreno C., Lifely M. R., Esdaile J. Immunity and protection of mice against Neisseria meningitidis group B by vaccination, using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide. Infect Immun. 1985 Feb;47(2):527–533. doi: 10.1128/iai.47.2.527-533.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  20. Peltola H., Safary A., Käyhty H., Karanko V., André F. E. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics. 1985 Jul;76(1):91–96. [PubMed] [Google Scholar]
  21. Reingold A. L., Broome C. V., Hightower A. W., Ajello G. W., Bolan G. A., Adamsbaum C., Jones E. E., Phillips C., Tiendrebeogo H., Yada A. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet. 1985 Jul 20;2(8447):114–118. doi: 10.1016/s0140-6736(85)90224-7. [DOI] [PubMed] [Google Scholar]
  22. Rosenqvist E., Harthug S., Frøholm L. O., Høiby E. A., Bøvre K., Zollinger W. D. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol. 1988 Aug;26(8):1543–1548. doi: 10.1128/jcm.26.8.1543-1548.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ross S. C., Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984 Sep;63(5):243–273. [PubMed] [Google Scholar]
  24. Saukkonen K., Abdillahi H., Poolman J. T., Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development. Microb Pathog. 1987 Oct;3(4):261–267. doi: 10.1016/0882-4010(87)90059-3. [DOI] [PubMed] [Google Scholar]
  25. Sjöholm A. G., Kuijper E. J., Tijssen C. C., Jansz A., Bol P., Spanjaard L., Zanen H. C. Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med. 1988 Jul 7;319(1):33–37. doi: 10.1056/NEJM198807073190106. [DOI] [PubMed] [Google Scholar]
  26. Tsai C. M., Frasch C. E., Mocca L. F. Five structural classes of major outer membrane proteins in Neisseria meningitidis. J Bacteriol. 1981 Apr;146(1):69–78. doi: 10.1128/jb.146.1.69-78.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wahdan M. H., Rizk F., el-Akkad A. M., el-Ghoroury A. A., Hablas R., Girgis N. I., Amer A., Boctar W., Sippel J. E., Gotschlich E. C. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ. 1973 Jun;48(6):667–673. [PMC free article] [PubMed] [Google Scholar]
  28. Wedege E., Frøholm L. O. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun. 1986 Feb;51(2):571–578. doi: 10.1128/iai.51.2.571-578.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Wedege E., Michaelsen T. E. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine. J Clin Microbiol. 1987 Aug;25(8):1349–1353. doi: 10.1128/jcm.25.8.1349-1353.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Williamson W. A., Greenwood B. M. Impairment of the immune response to vaccination after acute malaria. Lancet. 1978 Jun 24;1(8078):1328–1329. doi: 10.1016/s0140-6736(78)92403-0. [DOI] [PubMed] [Google Scholar]
  31. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES